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Abstract
Objective: The objective of the study was to characterize changes in the oral
clearance (CL/F) of lamotrigine (LTG) over the course of pregnancy and the
postpartum period through a model-based approach incorporating clinical
characteristics that may inﬂuence CL/F, in support of developing clinical man-
agement guidelines. Methods: Women receiving LTG therapy who were preg-
nant or planning pregnancy were enrolled. Maternal blood samples were
collected at each visit. A pharmacokinetic analysis was performed using a popu-
lation-based, nonlinear, mixed-effects model. Results: A total of 600 LTG con-
centrations from 60 women (64 pregnancies) were included. The baseline LTG
CL/F was 2.16 L/h with a between-subject variability of 40.6%. The inﬂuence of
pregnancy on CL/F was described by gestational week. Two subpopulations of
women emerged based on the rate of increase in LTG CL/F during pregnancy.
The gestational age-associated increase in CL/F displayed a 10-fold higher rate
in 77% of the women (0.118 L/h per week) compared to 23% (0.0115 L/h per
week). The between-subject variability in these slopes was 43.0%. The increased
CL/F at delivery declined to baseline values with a half-life of 0.55 weeks. Inter-
pretation: The majority of women had a substantial increase in CL/F from 2.16
to 6.88 L/h by the end of pregnancy, whereas 23% of women had a minimal
increase. An increase in CL/F may correspond to decreases in LTG blood con-
centrations necessitating the need for more frequent dosage adjustments and
closer monitoring in some pregnant women with epilepsy. Postpartum doses
should be tapered to preconception dose ranges within 3 weeks of delivery.
Introduction
Epilepsy and bipolar disorder are common conditions
that often require continuous treatment with antiepilep-
tic drugs (AEDs) during pregnancy to protect the
mother and the developing fetus from the harmful
effects of uncontrolled disease. Lamotrigine (LTG) is a
clinically viable option to treat epilepsy and bipolar dis-
order in pregnant women
1,2 in large part due to low rel-
ative risks of teratogenic complications and adverse
neurodevelopmental effects compared to other medica-
tion options.
3–8 However, LTG pharmacokinetics mark-
edly change during pregnancy
9–18 and if a woman with
epilepsy remains on her pre-pregnancy LTG dose, con-
centrations may decrease signiﬁcantly and lead to an
increase in seizure frequency for some women.
10,13,19
The clinical impact of declining LTG concentrations
during pregnancy in women with bipolar disorder is less
clear. The American Academy of Neurology Guidelines
states that monitoring of LTG levels during pregnancy
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99should be considered (Level B), but these guidelines fall
short of providing speciﬁc recommendations regarding
frequency and/or gestational timing of monitoring. This
is complicated further by the marked individual variabil-
ity seen in LTG clearance across pregnancy.
10,15 More
systematic information is needed regarding LTG phar-
macokinetic alterations during pregnancy and postpar-
tum to direct clinical care during these vulnerable life
stages.
20 In the United States, many neurologists moni-
tor LTG blood levels frequently when treating women
with epilepsy during pregnancy, but practices vary
between once per trimester to once per week. Con-
versely, perinatal monitoring of LTG concentrations has
not emerged as a common practice among psychiatrists
treating women with bipolar disorder.
LTG is moderately protein bound (55%) and has a rel-
atively long half-life (23–37 h).
21–25 It is mainly metabo-
lized in the liver by UDP-glucuronosyltransferases (UGT)
1A4.
26–28 UGT1A4 is also present in the placenta
at term.
29 Previous studies demonstrate that LTG oral
clearance (CL/F) increases up to 250% during preg-
nancy
9–11,15,16 and rapidly declines to preconception val-
ues within 2–4 weeks post-delivery.
9,10,14–17 Estrogens but
not progestins reduce LTG serum levels in women receiv-
ing oral hormonal contraceptives.
30 The rising levels of
estrogens during pregnancy may induce the UGT enzyme
system
31 and consequently increase the metabolism of
LTG leading to decreases in LTG concentrations.
Several studies demonstrate changes in LTG CL/F dur-
ing gestation,
9–18 with one systematic analysis with 14
women showing that perinatal week is a predictor of CL/
F.
15 The objective of this study was to build a model to
describe the LTG CL/F time course changes during and
after pregnancy in a larger group of pregnant women
who are taking LTG as part of their usual clinical therapy.
This approach allowed us to evaluate the changes in CL/F
throughout pregnancy and to quantify between-subject
variability in the parameters that describe the change in
time course.
Methods
Study population
The study was approved by the Institutional Review
Board of Emory University School of Medicine. Subjects
included in this analysis were women ≥17 years of age
treated with LTG for epilepsy and/or a psychiatric disor-
der, most commonly bipolar. Patients received LTG for
the clinical indication of epilepsy, a psychiatric disorder,
or both. For this study, exclusion criteria included signiﬁ-
cant medical issues (uncontrolled thyroid disease, severe
anemia, kidney or liver dysfunction or progressive cere-
bral disease), use of alcohol or recreational drugs, history
of medication nonadherence, inability to keep daily
seizure diaries personally or with the help of a caregiver if
the woman had epilepsy, and active suicidal ideation.
Written informed consent was obtained from each
woman before enrollment. Some subjects used in this
population-based pharmacokinetic analysis have been
included in a previous analysis.
10
Study design
Pregnant women or those planning a pregnancy were
enrolled in a prospective observational study to investi-
gate pharmacokinetic changes in neurotropic agents
including AEDs during pregnancy (Emory Women’s Epi-
lepsy and Women’s Mental Health Programs). All women
in the epilepsy cohort recorded use of all medications
and missed LTG doses in a daily diary; women with epi-
lepsy combined this with daily seizure diaries. Patients
were followed every 1–3 months during pregnancy and
the ﬁrst postpartum year. For women with epilepsy, a
neurologic examination and review of subject diary were
completed at each visit. In women with bipolar disorder,
a structured clinical interview for DSM-IV diagnosis
was completed in conjunction with serial administration
of symptom rating scales at visits scheduled every
4–6 weeks. In addition, intervening illnesses and obstetri-
cal complications, if any, were recorded for all partici-
pants. At each visit, body weight (WT), body mass index
(BMI), and gestational age (GA) in weeks or postpartum
weeks (PPW) were recorded. Maternal blood was col-
lected at each study visit and occasionally at obstetric
ofﬁces. Thus, the LTG concentrations were not necessar-
ily trough levels. Hours post dose were recorded. For epi-
lepsy patients, doses were adjusted for each subject
depending on her clinical status and comparison of the
clinically obtained LTG concentrations to the individual’s
baseline target concentration. For patients with bipolar
disorder, doses were adjusted at the discretion of the
treating psychiatrist in response to evolving presentation
of symptoms.
LTG concentration analysis
Blood was centrifuged at 1691 g,3 °C for 10 min, and
600 lL aliquots of plasma/serum were transferred to
polypropylene tubes. The plasma/serum samples were fro-
zen at  80°C until analysis. Total LTG concentrations
were measured using a validated assay employing high
performance liquid chromatography with ultraviolet
detection (Chromsystems, GmbH, Munich, Germany).
32
The lower and upper limit of quantiﬁcation of the bioan-
alytical assay was 0.25 and 20 lg/mL, respectively. Both
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(CVs) were <12.5%.
Pharmacokinetic analysis
The pharmacokinetic analysis was performed using a pop-
ulation-based, nonlinear, mixed-effects model (NONMEM
version 7; ICON Development Solutions, Ellicott City,
MD). LTG exhibits ﬁrst-order linear pharmacokinetics
that can be well described by a one compartmental
model.
33 Due to the relatively long time period between
pregnancies, women who had a second pregnancy were
treated as independent subjects. We chose to model all
observations as being steady state concentrations. This
decision was based on two important characteristics of
this dataset. First, LTG elimination half-life (23–37 h) is
relatively long compared to dosing intervals in the major-
ity of the patients. This results in minimal changes in
concentrations in the course of a day. Also, as volume of
distribution is suspected to increase over the course of
pregnancy we would need to have data to estimate the
parameter. This dataset did not include information that
allowed estimation of volume of distribution. Blood sam-
ples were obtained at least 7 days after any change in
maternal daily dose and steady state conditions were
assumed. As observed concentrations could be assumed
to be at steady state and ﬂuctuating little over the dosing
interval, they could be reasonably predicted using a steady
state infusion model (eq. 1).
Cobs ¼
DoseRate
CL=F
(1)
where the Dose Rate is the LTG total daily dose divided
by 24 h and CL/F is the apparent clearance of LTG.
Primary modeling efforts were focused on characteriz-
ing the time course of changes in LTG CL/F before preg-
nancy, during pregnancy, and after delivery. Intuitively,
our model needed to capture a pre-pregnancy CL/F,
some functional form that allowed CL/F to increase dur-
ing pregnancy with a relatively rapid decrease following
delivery, and a stable postpartum CL/F. The characteris-
tics of this model can be seen in Figure 1. In addition,
our modeling approach tested the effect of subject char-
acteristics of maternal and GA, body size, indication
(epilepsy or no epilepsy), and race on LTG CL/F (v
2,
Figure 1. Individual estimates (post hoc estimates) of LTG CL/F during different stages of pregnancy. Maroon and blue data points indicate the
post hoc CL/F estimates for subjects with higher rate of increase (population I) and lower rate of increase (population II) in CL/F during pregnancy,
respectively. Solid lines through the data indicate population predicted CL/F proﬁles. Vertical dashed lines at gestational age 0 and 40 weeks
separate stages of pregnancy (<0 weeks: preconception; 0–40 weeks: pregnant; >40 weeks: postpartum). Inset plot displaying the data and
population model predictions of ﬁrst four postpartum weeks. Horizontal dashed line in the plot represents baseline CL/F (2.16 L/h).
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evaluated for precision and internal predictive ability
using a bootstrap procedure and standardized visual pre-
dictive checks, respectively. For a detailed description of
the NONMEM modeling methodology, see the data sup-
plement for this article.
Results
Study population
Sixty women (64 pregnancies) met the inclusion criteria
providing 600 total LTG concentrations over the perinatal
period. Forty-three pregnancies were in women diagnosed
with epilepsy, 19 pregnancies in women with a psychiatric
illness, and two pregnancies in patients with a comorbidi-
ty of epilepsy and a psychiatric illness. Baseline character-
istics of the subjects are presented in Table 1.
Distribution of the time of observations during the course
of the study is presented in Table 2. Women were treated
with LTG daily doses (50–1400 mg) over the course of
the perinatal period. The majority of subjects were pre-
scribed a twice-a-day dosing schedule (73%). Four obser-
vations were excluded from the analysis because of
missing dose information.
Pharmacokinetic analysis
The ﬁnal model equations of LTG CL/F during pregnancy
and postpartum are presented in Table 3. The simulta-
neous ﬁtting of these model equations resulted in
physiologically meaningful parameter estimates with con-
siderable precision (Table 4). The baseline CL/F (CLBL)
was 2.16 L/h with a between-subject variability of 40.6%.
The stable postpartum CL/F was found to be no different
from the preconception value.
During pregnancy, the change in CL/F with GA was best
described by a linear function with a slope parameter.
Visual inspection of the plots of individual estimates of
CL/F versus GA revealed two different groups of women
each with a distinct rate of increase (slope) in CL/F
(Fig. 1). With the exception of GA and PPW, we were not
able to identify a covariate associated with these two
groups of women. Therefore, we modiﬁed our model of
the slope parameter to include two slopes using a mixture
model. In a mixture model, one proposes the population
is composed of subpopulations (two in our case) without
a priori deﬁning subjects to be in one population or the
other. The NONMEM software assigns each subject to
each population to determine which subpopulation is
more likely given their data. The result is an estimate of
the slope parameter for each group and an estimate of the
fraction of subjects in each subpopulation. The mixture
model indicated that a majority of women (77%) had a
steeper slope of 0.118 L/h per week of GA, whereas 23%
of pregnant women displayed a signiﬁcantly ﬂatter slope
of 0.0115 L/h per week for each week of gestation. Any
woman who had data from two pregnancies fell into the
same group both times. This mixture model accounted for
76% of the between-subject variability in the slopes with a
remaining between-subject variability of 43%.
Following delivery, a ﬁrst-order monoexponential
decline in CL/F as a function of PPW described the
return of CL/F to baseline in the postpartum period with
Table 1. Summary of subject demographics.
Baseline characteristics Mean   SD or number
Number of subjects 60
Epilepsy 42
Non epilepsy 18
Number of pregnancies 64
Epilepsy 43
Non-epilepsy 21
Age (in years) 31.1   5.5
Body weight (in kgs) 64.3   12.7
Height (in meters) 1.65   0.06
BMI (in kg/m
2) 23.9   4.9
Race
Whites 44
Blacks 10
Asians 4
Native Americans 2
Ethnicity
Non-Hispanics 57
Hispanics 3
BMI, body mass index.
Table 2. Distribution of samples and time dependent changes in covariates (mean   SD) across the perinatal period.
Characteristic
PC
(GA < week 0)
TM1
(0 < GA ≤ 14 weeks)
TM2
(14 < GA ≤ 28 weeks)
TM3 (28 weeks <
GA < delivery)
PP (delivery to
postpartum 70 weeks)
Subjects/pregnancies (n)1 3 3 6 4 5 5 4 5 1
Maternal blood samples (n) 35 88 139 161 177
Body weight (in kgs) 68.9   14.4 66.1   11.6 71.5   14.4 75.5   13.2 69.9   15.4
BMI (in kg/m
2) 26.0   5.0 24.5   4.5 27.1   6.0 28.1   5.0 25.8   5.7
PC, preconception; TM, trimester; PP, postpartum; GA, gestational age; BMI, body mass index.
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of 0.55 weeks.
After taking into account the effects of both GA and
PPW and allowing two slopes with the mixture model,
the remaining unexplained variability was 45.7%. Mater-
nal body size, maternal age, indication (epilepsy or no
epilepsy), and race had no effect on any portion of our
model (v
2, P > 0.05, df = 1). The simulation-based
model evaluation conﬁrmed the internal predictive per-
formance of the ﬁnal model (see supplement for more
detail).
Discussion
We characterized the changes in LTG oral CL before and
during the course of pregnancy and in PPW with a non-
linear mixed-effects approach. A unique ﬁnding of our
model-based analysis is the identiﬁcation of two popula-
tions of women with different rates of increase in CL/F.
Overall, data were adequately characterized by a linear
increase in LTG CL/F during pregnancy and a nonlinear
exponential decline in CL/F after delivery. The population
mean baseline CL/F (CLBL) of 2.16 L/h is in close agree-
ment with those reported (1.96–2.64 L/h) from other
studies.
21–25,34–38 Furthermore, the magnitude of the
between-subject variability in both the baseline CL/F
(40.6%) and increased rates of oral CL (43.0%) during
pregnancy are consistent with previous reports that noted
a substantial interindividual variability in CL/F rates dur-
ing pregnancy.
10,15,39
Interestingly, while most women demonstrate a sub-
stantial increase in LTG CL/F during pregnancy, we iden-
tiﬁed a subpopulation of pregnant women that exhibited a
very modest increase (Fig. 1). The main population
included a majority of the pregnant women (77%) and
displayed a 10-fold increase in LTG CL/F per week com-
pared to the subpopulation. The estimated rate of increase
in LTG CL/F for the main population (0.118 L/h per
week) predicts 76%, 153%, and 219% increases of CL/F
from baseline, while that of population II (0.0115 L/h per
week) confers lower degrees of increase in LTG oral CL
(7.5%, 15%, and 21%) by the end of the conventional ﬁrst
(14 weeks), second (28 weeks), and third (40 weeks) tri-
mesters, respectively. Our estimated changes in LTG CL/F
during pregnancy are in general agreement with previous
studies of pregnant women that reported increases of 65–
197%, 93–236%, and 88–250% in baseline LTG CL/F for
the ﬁrst, second and third trimesters, respectively.
9–11,15,16
Genotypic variations in the activity or induction of
UGT1A4 could partly explain the varying degrees of
enhanced oral CL between the two populations and may
warrant further investigations.
16,40–42
These ﬁndings are of clinical importance as they indi-
cate that varying degrees of change in LTG CL/F are
expected during gestation with some patients displaying a
dramatic increase in their oral CL compared to others.
Table 3. Final model equations.
Stage Model equation Description
Preconception CL/F = CLBL CLBL: baseline CL/F
Pregnant Population I: CL/F = CLBL + Slope1 9 GA GA: gestational age
Population II: CL/F = CLBL + Slope2 9 GA Slope: rate of change in CL/F
Postpartum CL/F = ΔCLDEL 9 exp ( k 9 PPW) + CLBL ΔCLDEL: CL/F change from baseline to delivery; k:
ﬁrst-order rate constant; PPW: postpartum weeks
Table 4. Final model parameter estimates.
Stage of pregnancy Parameter Estimate (% RSE)
Bootstrap median [2.5th,
97.5th percentile]
Preconception CLBL (L/h) 2.16 (6.4) 2.14 [1.90, 2.47]
BSV in CLBL (% CV) 40.6 39.6
Pregnant Slope1 (L/h per week) 0.118 (11.4) 0.117 [0.067, 0.155]
Slope2 (L/h per week) 0.0115 (53.0) 0.0115 [0.0012, 0.0872]
Mixing fraction (population II) 0.23 (34.1) 0.25 [0.09, 0.617]
BSV in slope (% CV) 43.0 40.0
Postpartum k (1/week) 1.27 (10.5) 1.29 [1.09, 4.54]
RUV (% CV) 45.7 45.5
CLBL, baseline clearance; BSV, between-subject variability; RUV, residual unexplained variability; % CV, percent coefﬁcient of variation; % RSE,
percent relative standard error.
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women with the larger increase in CL/F may require more
frequent and higher dosage adjustments in order to main-
tain pre-pregnancy baseline levels. This group may also
display greater variability in LTG concentrations during
pregnancy than those in the smaller subpopulation of
women exhibiting a minimal increase in LTG oral CL
over the weeks of gestation.
In the PPW, the LTG CL/F declined in an exponential
manner with a common estimated ﬁrst-order rate con-
stant (k) of 1.27 per week for both subpopulations. The
calculated half-life (0.693/k) of the return to baseline CL/
F was 0.55 weeks, indicating that LTG oral CL is expected
to reach the baseline value within 3 weeks after delivery.
This is consistent with the previous report from this study
group stating that an empiric postpartum taper over the
ﬁrst 10 days to the preconception dose or preconception
dose plus 50 mg prevents postpartum toxicity symptoms;
in some women, preconception dose plus 50 mg was cho-
sen to counteract the seizure-provoking effects of the
inevitable sleep-disruption.
10 In addition, several previous
studies determined a postpartum period of 2–4 weeks for
LTG CL/F to reach preconception values in pregnant
women receiving LTG.
9,10,14–17
After accounting for GA and PPW, weight, race, clini-
cal diagnosis/indication, and age were found to have no
effect on LTG oral CL. Similarly, in a study of pregnant
women maintained on LTG monotherapy Pennell et al.
15
found the changes of LTG oral CL during pregnancy and
childbirth to be independent of WT. This is consistent
with clinical observation in epilepsy patients that dose
changes are needed in the ﬁrst trimester even though
there are small to no weight changes at this time in the
pregnancy. Regarding age, our results remain consistent
with the Pennell et al.
10 study who found the age of preg-
nant women to have no signiﬁcant effect on LTG oral
CL. The population of our study consisted of women of
child-bearing age; therefore, by nature this population
reﬂects a narrow age range (17–42 years) and may explain
the lack of an age effect on LTG CL/F.
The satisfactory performance of the oral CL model
may justify its applicability in dosing pregnant women
on LTG monotherapy and those on LTG with no inter-
acting medications. Once a patient’s pattern of induc-
tion of clearance is determined during the ﬁrst
trimester or in a previous pregnancy, it may be possible
to adjust the schedule for blood draws. For instance, if
LTG concentrations drop by approximately 50% at the
end of the ﬁrst trimester it is likely the women will
continue to exhibit increasing clearances throughout
pregnant. The majority of women in the main subpop-
ulation will likely require therapeutic drug monitoring
at least once per month until delivery, while it may be
possible to reduce the frequency of blood sampling to
every 2–3 months in a smaller subpopulation of women.
It may even be possible to make empiric dosage adjust-
ments in this group if they have barriers to frequent
blood draws such as cost or transportation. Further
prospective studies that test the utility of this equation
are needed.
In conclusion, we characterized the changes of LTG
CL/F during the course of pregnancy and after delivery
using a model-based approach. The major results of this
analysis showed that LTG CL/F was signiﬁcantly inﬂu-
enced by GA and PPW and identiﬁed the presence of
two subpopulations of women with different rates of
increases in CL/F during pregnancy. The rate of LTG
clearance differed by 10-fold between groups with an
estimated mixing fraction of 23% in the subpopulation
meaning that during pregnancy, LTG CL/F increases
from 2.16 L/h to 6.88 L/h in 77% of women, while in
the remaining 23%, CL/F increases from the 2.16 L/h to
only 2.62 L/h. This 219% increase in CL/F in the major-
ity of women translates to a possible need for a substan-
tial increase in daily LTG dose over the course of
pregnancy to maintain a woman with an epilepsy
patient’s individual target concentration to avoid seizure
worsening, and will almost certainly require close moni-
toring of concentrations. In the smaller group, the 21.3%
increase in CL/F may not even necessitate an increase in
dose. Unfortunately, no covariates could be identiﬁed to
indicate which group any individual woman belonged.
Further studies incorporating genotyping information
and possibility of polymorphisms involved in the regula-
tion and expression of UGT1A4 or induction-related
estrogen receptors could be useful to identify the deter-
minant of variation in LTG CL/F during pregnancy. Fol-
lowing childbirth, CL/F rapidly reached preconception
values within 3 weeks. Thus, LTG doses should be
tapered to preconception doses or slightly above within
3 weeks of delivery. Characterization of the factors inﬂu-
encing LTG CL/F will be valuable in optimizing the clin-
ical management of women on LTG across the perinatal
period. In addition, these factors may also be important
considerations for management of other medications
across the perinatal period.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Data S1. Details of pharmacokinetic modeling and eva-
luation.
Figure S1. Observed versus population predicted (PRED)
and observed versus individual predicted (IPRED) LTG
concentrations, by stage of pregnancy (PC, preconception;
PP, postpartum). Data points indicate the observed versus
predicted plasma concentrations. Solid straight line pass-
ing through origin is a line of identity and dashed line is
a smooth for observed versus predicted concentrations.
Figure S2. Conditional weighted residuals (CWRES) ver-
sus population predicted (PRED) LTG concentrations, by
stage of pregnancy (PC, preconception; PP, postpartum).
A solid line (y = 0) is included as a reference for CWRES.
Dashed line is a smooth for CWRES versus PRED con-
centrations.
Figure S3. Conditional weighted residuals (CWRES) ver-
sus gestational age (GA). A solid line (Y = 0) is included
as a reference for CWRES. Black dashed line is a smooth
for CWRES versus GA.
Figure S4. Standardized visual predictive check (SVPC)
plot of the ﬁnal model. Pi,j, a percentile for the jth obser-
vation of the ith individual calculated from the marginal
distribution of the model-simulated concentrations. Open
circles, calculated Pi,j values; dashed lines, 5th, 50th, and
95th percentiles (from bottom to top). Vertical bold
dashed line at 40 weeks represents approximate time of
delivery (0 weeks: preconception; 0–40 weeks: pregnant;
>40 weeks: postpartum).
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